Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC

Introduction: Statins, used for their lipid-lowering activity, have anti-inflammatory and anticancer properties as well. We evaluated this potential benefit of statin use in patients with NSCLC. Methods: All 613 patients with pathologic stage 1 or 2 NSCLC who had lobectomy without neoadjuvant therap...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Santosh K. Patnaik, MD, PhD, Cara Petrucci, PhD, Joseph Barbi, PhD, Robert J. Seager, PhD, Sarabjot Pabla, PhD, Sai Yendamuri, MD
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Body mass index Lung cancer Obesity Statin Tumor immunity Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/589bd2c2b95241a8bf3e7e8688a886b5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:589bd2c2b95241a8bf3e7e8688a886b5
record_format	dspace
spelling	oai:doaj.org-article:589bd2c2b95241a8bf3e7e8688a886b52021-11-28T04:38:44ZObesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC2666-364310.1016/j.jtocrr.2021.100254https://doaj.org/article/589bd2c2b95241a8bf3e7e8688a886b52021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666364321001132https://doaj.org/toc/2666-3643Introduction: Statins, used for their lipid-lowering activity, have anti-inflammatory and anticancer properties as well. We evaluated this potential benefit of statin use in patients with NSCLC. Methods: All 613 patients with pathologic stage 1 or 2 NSCLC who had lobectomy without neoadjuvant therapy at our institution during 2008 to 2015 were included. Association between presurgery statin use and overall survival and recurrence-free survival (RFS) was analyzed using Cox proportional hazards regression. Association of statin use with tumor transcriptome was evaluated in another 350 lung cancer cases. Results: Univariable analyses did not reveal a statistically significant association of statin use with either overall survival or RFS, with hazard ratio equals to 1.19 and 0.70 (Wald p = 0.28 and 0.09), respectively. In subgroup analyses, significantly improved RFS was found in statin users, but only in overweight/obese patients (body mass index [BMI] > 25; n = 422), with univariable and multivariable hazard ratio of 0.49 and 0.46 (p = 0.005 and 0.002), respectively, but not in patients with BMI less than or equal to 25 (n = 191; univariable p = 0.21). Transcriptomes of tumor statin users had high expression of tumoricidal genes such as granzyme A and interferon-γ compared with those of nonusers among high- but not low-BMI patients with lung cancer. Conclusions: Our study suggests that statins may improve the outcome of early stage NSCLC but only in overweight or obese patients. This benefit may stem from a favorable reprogramming of the antitumor immune response that statins perpetrate specifically in the obese.Santosh K. Patnaik, MD, PhDCara Petrucci, PhDJoseph Barbi, PhDRobert J. Seager, PhDSarabjot Pabla, PhDSai Yendamuri, MDElsevierarticleBody mass indexLung cancerObesityStatinTumor immunityNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJTO Clinical and Research Reports, Vol 2, Iss 12, Pp 100254- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Body mass index Lung cancer Obesity Statin Tumor immunity Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Body mass index Lung cancer Obesity Statin Tumor immunity Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Santosh K. Patnaik, MD, PhD Cara Petrucci, PhD Joseph Barbi, PhD Robert J. Seager, PhD Sarabjot Pabla, PhD Sai Yendamuri, MD Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC
description	Introduction: Statins, used for their lipid-lowering activity, have anti-inflammatory and anticancer properties as well. We evaluated this potential benefit of statin use in patients with NSCLC. Methods: All 613 patients with pathologic stage 1 or 2 NSCLC who had lobectomy without neoadjuvant therapy at our institution during 2008 to 2015 were included. Association between presurgery statin use and overall survival and recurrence-free survival (RFS) was analyzed using Cox proportional hazards regression. Association of statin use with tumor transcriptome was evaluated in another 350 lung cancer cases. Results: Univariable analyses did not reveal a statistically significant association of statin use with either overall survival or RFS, with hazard ratio equals to 1.19 and 0.70 (Wald p = 0.28 and 0.09), respectively. In subgroup analyses, significantly improved RFS was found in statin users, but only in overweight/obese patients (body mass index [BMI] > 25; n = 422), with univariable and multivariable hazard ratio of 0.49 and 0.46 (p = 0.005 and 0.002), respectively, but not in patients with BMI less than or equal to 25 (n = 191; univariable p = 0.21). Transcriptomes of tumor statin users had high expression of tumoricidal genes such as granzyme A and interferon-γ compared with those of nonusers among high- but not low-BMI patients with lung cancer. Conclusions: Our study suggests that statins may improve the outcome of early stage NSCLC but only in overweight or obese patients. This benefit may stem from a favorable reprogramming of the antitumor immune response that statins perpetrate specifically in the obese.
format	article
author	Santosh K. Patnaik, MD, PhD Cara Petrucci, PhD Joseph Barbi, PhD Robert J. Seager, PhD Sarabjot Pabla, PhD Sai Yendamuri, MD
author_facet	Santosh K. Patnaik, MD, PhD Cara Petrucci, PhD Joseph Barbi, PhD Robert J. Seager, PhD Sarabjot Pabla, PhD Sai Yendamuri, MD
author_sort	Santosh K. Patnaik, MD, PhD
title	Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC
title_short	Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC
title_full	Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC
title_fullStr	Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC
title_full_unstemmed	Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC
title_sort	obesity-specific association of statin use and reduced risk of recurrence of early stage nsclc
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/589bd2c2b95241a8bf3e7e8688a886b5
work_keys_str_mv	AT santoshkpatnaikmdphd obesityspecificassociationofstatinuseandreducedriskofrecurrenceofearlystagensclc AT carapetrucciphd obesityspecificassociationofstatinuseandreducedriskofrecurrenceofearlystagensclc AT josephbarbiphd obesityspecificassociationofstatinuseandreducedriskofrecurrenceofearlystagensclc AT robertjseagerphd obesityspecificassociationofstatinuseandreducedriskofrecurrenceofearlystagensclc AT sarabjotpablaphd obesityspecificassociationofstatinuseandreducedriskofrecurrenceofearlystagensclc AT saiyendamurimd obesityspecificassociationofstatinuseandreducedriskofrecurrenceofearlystagensclc
_version_	1718408259313860608

Obesity-Specific Association of Statin Use and Reduced Risk of Recurrence of Early Stage NSCLC

Ejemplares similares